PhorMed

PhorMed

Growth Stage

Utilizing gene therapy to target cancer and mutated cells

Utilizing gene therapy to target cancer and mutated cells

Overview

Raised to Date: Raised: $243,864

Total Commitments ($USD)

Platform

StartEngine

Start Date

05/23/2022

Close Date

08/17/2022

Min. Goal
$10,000
Max. Goal
$2,150,494
Min. Investment

$500

Security Type

Equity - Common

Series

Seed

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$1.00

Pre-Money Valuation

$51,647,023

Rolling Commitments ($USD)

Status
Funded
Reporting Date

08/30/2022

Days Remaining
Funded
% of Min. Goal
Funded
% of Max. Goal
Funded
Likelihood of Max
Funded
Avg. Daily Raise

$2,869

# of Investors

210

Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded

2019

Industry

Healthcare & Pharmaceuticals

Tech Sector

Biotech

Distribution Model

B2B/B2C

Margin

Medium

Capital Intensity

High

Location

Beverly Hills, California

Business Type

Growth

PhorMed, with a valuation of $51.6 million, is raising funds on StartEngine. It is a biopharmaceutical company that is changing the face of genomic medicine. PhorMed uses gene therapy to target and treat cancer cells and mutated cells, and is developing a treatment for patients suffering from Hodgkin’s Lymphoma, Parkinson’s Disease, and Acute Myeloid Leukemia. PhorMed uses a leading technology, RP-323, as its gene repair therapy. The drug has completed Phase 1 of the clinical study and has generated positive outcomes. Ben Chang founded PhorMed in May 2019. The current crowdfunding campaign has a minimum target of $10,000 and a maximum target of $2,150,494. The campaign proceeds will be used for growth and expansion.

Summary Profit and Loss Statement

Most Recent Year Prior Year

Revenue

$0

$0

COGS

$0

$0

Tax

$0

$0

 

 

Net Income

$-573,854

$-948,160

Summary Balance Sheet

Most Recent Year Prior Year

Cash

$105,694

$109,844

Accounts Receivable

$0

$0

Total Assets

$183,724

$340,922

Short-Term Debt

$227,264

$363,294

Long-Term Debt

$0

$0

Total Liabilities

$227,264

$363,294

Financials as of: 05/23/2022
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
PhorMed 04/28/2024 Wefunder $52,523,767 $0 Equity - Common Active RegCF
PhorMed 08/16/2022 StartEngine $51,647,023 $243,864 Equity - Common Funded RegCF
PhorMed 03/24/2022 StartEngine $39,000,000 $2,450,528 Equity - Common Funded RegCF
Create a free account today to gain access to KingsCrowd analytics.

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Valuation History

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Employee History

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
PhorMed on StartEngine 2022
Platform: StartEngine
Security Type: Equity - Common
Valuation: $51,647,023
Price per Share: $1.00

Follow company

Follow PhorMed on StartEngine 2022

Buy PhorMed's Deal Report

Warning: according to the close date for this deal, PhorMed may no longer be accepting investments.

PhorMed Deal Report

Get KingsCrowd’s comprehensive report on PhorMed including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether PhorMed is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the PhorMed deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge